Sandoz Builds Its Biologics Portfolio For Europe, Not US, Says CEO Saynor
But Shifts Focus To Increase US Market Share For Its Own Humira Biosimilar
At the recent Jefferies Global Healthcare Conference in London, Sandoz’s CEO Richard Saynor colorfully shared the firm’s dreams and achievements, and the market’s current state of play.
